Status:
COMPLETED
Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes
Lead Sponsor:
Mayo Clinic
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ult...
Detailed Description
Multiple daily insulin injection (MDI) programs are commonly accompanied by considerable glycemic variation and hypoglycemia. In order to determine whether use of insulin glargine as a basal insulin w...
Eligibility Criteria
Inclusion
- Type 1 diabetes, HbA1c \< 7.8%, who have had prior instruction in a complex insulin program, and presently using a MDI insulin program with basal insulin preparations of Glargine or Ultralente and Humalog as the short acting insulin, should be free of hepatorenal abnormalities and hypoglycemia unawareness; non-pregnant, and should be able to perform frequent self monitoring of blood glucose (SMBG) and accept the use of continuous glucose monitoring system (CGMS). They should also possess the skill and understanding of insulin dose adjustments and supplementation.
Exclusion
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00276393
Start Date
July 1 2002
End Date
December 1 2003
Last Update
May 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905